Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 18, 2013

Ablynx, Eddingpharm Ink License Agreement to Develop Nanobody Therapeutics in China

  • Ablynx granted Eddingpharm an exclusive license to develop and commercialize ALX-0141, Ablynx’ anti-RANKL nanobody, for all indications including osteoporosis and bone metastases in China, Hong Kong and Macao, and Taiwan.

    Ablynx will receive a €2 million (approximately $2.7 million) up-front payment from Eddingpharm and is entitled to commercial milestone payments plus tiered, double-digit royalties of up to 20%, based on annual net sales of ALX-0141 generated by Eddingpharm in greater China.

    Under the agreement, Eddingpharm will be responsible for the clinical development, registration, and commercialization of anti-RANKL nanobody therapeutics. Ablynx will have access to the data generated by Eddingpharm to support potential licensing discussions in other geographic regions.

    According to Ablynx, ALX-0141 is a bivalent bi-specific therapeutic molecule composed of two nanobodies targeting the Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). The bivalent anti-RANKL construct is linked to a nanobody that binds to serum albumin, which extends the drug's in vivo half-life and may lead to preferential targeting of diseased tissue.

    Last month, Ablynx partnered with Merck Serono on developing the former’s Nanobodies®—therapeutic proteins based on single-domain antibody fragments—against multiple targets in the latter’s core therapeutic areas. As part of the research alliance, Ablynx received an up-front payment of €11.5 million ($15.5 million) and will net €25 million ($33.7 million) in research funding from Merck Serono over its four-year term.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »